Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to […]

Read More

“SCG – CPAC” and “Samsung E&A” sign MOU to bolster 3D printing technology and special cementitious materials in global market

BANGKOK, THAILAND – Media OutReach Newswire – 2 September 2024 – On behalf of CPAC, a cement and building materials company under Siam Cement Group (SCG), Mr. Thammasak Sethaudom, President & CEO of SCG (second from the left), and Mr. Surachai Nimlaor, President of SCG Cement and Green Solution Business (first from the left), signed the Memorandum of Understanding (MoU) with Mr. Hong […]

Read More